TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07476001: Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07476001 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07476001 Rescue Dossier →